Journal of the National Cancer Institute Advance Access originally published online on November 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(23):1741-1743; doi:10.1093/jnci/djm245
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press.
EDITORIALS |
18Fluorodeoxyglucose Positron Emission Tomography, a Standard Diagnostic Tool in Lung Cancer
Affiliation of author: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
Correspondence to: Giuseppe Giaccone, PhD, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD (e-mail: giacconeg@mail.nih.gov).
| The first 10% of the full text of this article appears below. |
18Fluorodeoxyglucose positron emission tomography (FDG-PET) has entered routine use in the management of lung cancer, at least in countries and health systems that can afford it. FDG-PET has better sensitivity than computed tomography (CT) scanning in the detection of distant metastases in patients with non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, the relatively low specificity of FDG-PET and the difficulty in localizing the "hot spots" identified by FDG-PET imaging have elicited efforts to integrate FDG-PET with other radiologic imaging techniques, such as CT scans.
In this issue of the Journal, Ung et al. (1) present an extensive systematic review of the published literature on the accuracy and utility of FDG-PET in the diagnosis and staging of lung cancer. The authors focus on three areas: 1) use of FDG-PET in
Solitary Pulmonary Nodules
Preoperative Staging of Non–Small Cell Lung Cancer
Staging of Small Cell Lung Cancer
Related Articles in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1753-1767.
J Natl Cancer Inst 2007 99: 1737.
J Natl Cancer Inst 2007 99: 1737.